Mājaslapas jaunā versija tapusi pateicoties Latvijas valsts budžeta finansētai programmai "NVO Fonds". Projektu finansiāli atbalsta Sabiedrības integrācijas fonds no Latvijas valsts budžeta līdzekļiem.
- Concept2016 is the year that marked a turning point in access to medicines debate in Europe. During the Dutch Presidency in the EU the current problems were named and analyzed – unjustifiably high prices, questionable innovative value of new drugs, business model that works well for the pharmaceutical industry but does not offer the best possible outcomes for patients and the society. Will the Baltic countries be able to seize the moment and raise their voices to stress the problems we encounter due to the small market and lower capability to reimburse the medicines with unreasonably high prices that lead to even bigger inequalities in the EU? How innovative are the new therapies? Are there altern
- ProgrammeOctober 13, 2017 | Albert Hotel, Riga, Dzirnavu street 33 ---------------- Conference Agenda 8.30 – 9.00 Registration 9.00 – 9.05 Welcoming Remarks Moderator - Tim Reed, Health Action International ---------------- Part I 9.05 – 9.30 Keynote Address Yannis Natsis | Policy Manager for Universal Access & Affordable Medicines, European Public Health Alliance (EPHA) 9.30 – 11.00 Panel session: Political Developments in Access to Medicines Debate in Europe. Where We Are and What Can be Done - Raf Mertens | General Director, Belgian Health Care Knowledge Centre - Erki Laidmae | Head of Insurance Benefit Package, Estonian Health Insurance Fund - Inese Kaupere | Director
- SpeakersYannis Natsis, European Public Health Alliance (EPHA).Yannis has studied EU affairs and conflict-resolution in Greece and the UK, has worked as an investigative reporter on award-winning Greek TV news program “Fakeli”, at the European Parliament, the Greek Ministry of Foreign Affairs and the private sector. Since 2013 when he started working for the TransAtlantic Consumer Dialogue, an NGO based in Brussels, Yannis has focused on access to medicines and intellectual property. In January 2016 he joined EPHA as Policy Manager Universal Access and Affordable Medicines and is an expert in policy developments in the field of medicines, issues of medical innovation and access of patients to their